GlobeNewswire

Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders

Share

Allschwil, Switzerland – April 1, 2021

Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending December 31, 2020 will be held on Wednesday May 12, 2021.

The meeting will be held in accordance with the requirements of the COVID 19 Ordinance 2, issued by the Swiss Federal Council. As a result, attendance in person will not be possible and voting will take place by independent proxy only.

Mathieu Simon, Chairman of the Board of Directors commented:
“Once again, we must prioritize the health of our shareholders and the Idorsia team, so we are unable to host our shareholders at an in-person meeting. I trust that our engaged shareholder base will make their voice heard none-the-less through the proxy vote. Among the usual governance topics, we continue to ensure the Board benefits from fresh perspectives by proposing Srishti Gupta and Peter Kellogg, two excellent new candidates to the Board. At the same time Viviane Monges and Michel de Rosen have decided not to stand for re-election this year. We thank both Viviane and Michel for their contribution to the Board during these critical years of Idorsia’s foundation.”

Notes to Shareholders
The Notice, which includes the biographies of proposed Board candidates, will be published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) in the coming days and distributed to Shareholders by post on April 16, 2021. It is also available, together with the Company’s Annual Report and Compensation Report, on www.idorsia.com/agm.

Shares only qualify for voting through the independent proxy if registered in the company's shareholder register by May 3, 2021 at the latest. Registered shareholders will receive a form to appoint the Independent Proxy. Forms must be received by May 7, 2021, please allow appropriate time for delivery given the strain on public resources.


Notes to the editor

Letter from the Chairman

Dear Shareholder,

Once again, the details of this year’s Annual General Meeting of Idorsia’s shareholders comes to you amid the continued COVID-19 pandemic. In this context we will be holding the event in accordance with the requirements of the COVID‑19 Ordinance 2, issued by the Swiss Federal Council. This means that attendance in person is not possible and voting will take place by independent proxy. Again, we must prioritize the health of our shareholders and the Idorsia team.

Let me therefore take this opportunity to provide you with some context and background information on the Board’s proposals, which you are invited to vote on either by postal vote or via the electronic voting platform.

To begin with, you will find a full description of last year’s activities in our Annual Report 2020 at: www.idorsia.com/annual-report.

In the report you will read about the excellent progress the company has made, despite the upheaval that the global pandemic has caused. The workforce was able to hunker down and deliver the read out of vital results from the global Phase 3 program with daridorexant, our investigational therapy for insomnia and the Japanese study of clazosentan for cerebral vasospasm as a consequence of an aneurysmal hemorrhage. Both these positive programs have been analyzed and are already filed with health authorities for review. In order to not miss a beat, the company also made great progress with establishing our global commercial capabilities, building out our infrastructure, support network and most importantly a stellar team.

Obviously, these huge achievements take the limelight, but the company also advanced other projects in the drug discovery and clinical development pipeline. The lab-based colleagues continued to show-up and make a difference, while the clinical development team took steps to ensure patients could safely participate in the ongoing studies. An outstanding effort all round.

During 2020, we went to the capital market to access funding which will take us a long way towards our goal to become a sustainable, leading biopharmaceutical company. With our first stream of revenue on the horizon from the revenue sharing agreement for ponesimod, and our own potential product launches getting closer with each day, we are assessing all options to bring the company to break even. However, we must maintain financial and strategic flexibility. To this end, we are asking you to approve an increase to authorized capital until the AGM in 2023.

In addition, we are asking you to approve an increase in the budget for the aggregate maximum amount of compensation for the Idorsia Executive Committee. This would give the Board more flexibility to increase the potential variable pay, should we consider this appropriate to incentivize and reward the successful launch of the company’s first products and other milestones planned for 2022, all of which are key to Idorsia’s future success and sustainability.

Continuing our efforts to ensure the Board benefits from fresh perspectives, we are proposing two new candidates to the Board. Srishti Gupta and Peter Kellogg both bring rich experiences to the company as we embark upon our first product launches. You can read more about our proposed candidates in their biographies in the Appendix to this invitation. At the same time Viviane Monges and Michel de Rosen have decided not to stand for re-election this year. We thank both Viviane and Michel for their contribution to the Board during these critical years of Idorsia’s foundation.

The other items on the agenda are relatively straightforward, and explanations are given with the proposal or in the Appendix.

I am very disappointed to not be able to meet with you in person at my first AGM as Chairman but I am sure that the excellent response from the pharmaceutical industry that has resulted in vaccines will mean we can return to some semblance of normality during this year.

I send you my best wishes for health in 2021, and I hope that you will exercise your voting rights through the proxy vote.

Best regards,
Mathieu Simon
Chairman of the Board of Directors


Agenda for the Annual General Meeting of Shareholders 2021

1.        Annual Report 2020, Consolidated Financial Statements 2020, Statutory Financial Statements 2020 and Compensation Report 2020
           1.1.      Approval of Annual Report 2020, Consolidated Financial Statements 2020 and Statutory Financial Statements 2020
           1.2.      Consultative vote on the Compensation Report 2020
2.        Appropriation of available earnings
3.        Discharge of the Board of Directors and of the Executive Committee
4.        Increase and extension of existing authorized share capital
5.        Board elections
           5.1.      Re-election of members of the Board of Directors
           5.2.      Election of new Directors
           5.3.      Election of the Chair of the Board of Directors
           5.4.      Election of the Compensation Committee
6.        Approval of Board compensation and Executive Committee compensation
           6.1.      Approval of Board compensation (Non-Executive Directors) for the 2021–2022 term of office
           6.2.      Approval of Executive Committee compensation 2022
7.        Election of the Independent Proxy
8.        Election of the statutory auditors

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV16.4.2021 17:40:00 CEST | Press release

Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV Since the quorum required for the Extraordinary General Meeting of Shareholders of 22 April 2021 will not be attained, ageas SA/NV is organising the Ordinary and Extraordinary Meeting of Shareholders (the "Meeting") on Wednesday 19 May 2021 at 10:30 a.m. The Meeting is being held at The Egg, Barastraat 175, 1070 Brussels, and is being organised in accordance with the Corona measures applicable on the day of the Meeting. Shareholders are advised to consult the Ageas website (www.ageas.com) for any additional information on this subject. If the current measures remain unchanged, it will not be permitted to physically attend the Meeting. In that case, registered shareholders who have indicated that they wish to vote online will be able to follow the Meeting via a webcast. They are invited to consult in advance the Ageas website, where the procedure to log in for the webcast will be published. Ag

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER16.4.2021 16:20:00 CEST | Press release

Bid procedure, 2021-04-21CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-10-21 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-04-09 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-04-21Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS16.4.2021 16:20:00 CEST | Press release

Bid procedure, 2021-04-21BillsSWEDISH T-BILL: SE0015811351. 2021-07-21 SWEDISH T-BILL: SE0014808747, 2021-09-15 Bid date2021-04-21Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0015811351: 1250 mln SEK +/-600 mln SEK SE0014808747: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0015811351: 1250 mln SEK per bid SE0014808747: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-23Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-04-16 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS16.4.2021 16:20:00 CEST | Press release

Bid procedure, 2021-04-23BondsSWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2021-04-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1053: 750 mln SEK +/-400 mln SEK 1063: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1053: 750 mln SEK per bid 1063: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-27Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-04-16 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS16.4.2021 16:20:00 CEST | Press release

Bid procedure, 2021-04-20BondsKOMMUNINVEST I SVERIGE: 2410. SE0010469205. 2024-10-02 KOMMUNINVEST I SVERIGE: 2602, SE0013745452, 2026-02-04 KOMMUNINVEST I SVERIGE: G23, XS1897258098, 2023-06-01 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-04-20Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2410: 500 mln SEK +/-250 mln SEK 2602: 500 mln SEK +/-250 mln SEK G23: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)2410: 500 mln SEK per bid 2602: 500 mln SEK per bid G23: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-22Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING16.4.2021 16:20:00 CEST | Press release

Bid date, 2021-04-23Auction Day2021-04-23Auction Time10.30-11.00 (CET/CEST) on the Bid dateOffered AmountSEK 50 billion (total)Maximum Permitted Bid VolumeSEK 12.5 billion from an individual bidder (in total per Auction Day)Settlement Date2021-04-27Minimum Permitted Bid VolumeSEK 10 million per bidMaximum Number of Bids per offered Repayment Date1Repayment Dates (offered maturities)29 April 2022 28 April 2023 30 April 2024Maximum Allocation25 per cent of Offered AmountAllocation TimeNot later than 11.30 (CET/CEST) hours on Auction dayBase Period (to establish Base Lending Amount)1 March 2020 - 28 February 2021Evaluation Rounds (for calculation of any Additional Interest)Evaluation Round 1: April 2022 (for Credit with Repayment Date 29 April 2022. 28 April 2023 and 30 April 2024) refers to Comparison Period 1: 1 March 2021 – 28 February 2022 and potential Additional Interest Rate applied to Lending Period 1: from 30 March 2021 up to and including 29 April 2022. Evaluation Round 2: April

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS16.4.2021 16:20:00 CEST | Press release

Bid procedure, 2021-04-22BondsSWEDBANK HYPOTEK AB: 194. SE0012142206. 2024-09-18 STADSHYPOTEK AB: 1587, SE0010441303, 2023-06-01 SWEDISH COVERED BOND: 147, SE0009383664, 2026-06-17 SKANDINAVISKA ENSKILDA: 576, SE0010049841, 2023-12-20 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-04-22Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)194: 800 mln SEK +/-400 mln SEK 1587: 2000 mln SEK +/-1000 mln SEK 147: 700 mln SEK +/-350 mln SEK 576: 700 mln SEK +/-350 mln SEK 520: 600 mln SEK +/-300 mln SEK 2512: 200 mln SEK +/-100 mln SEK 5536: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)194: 800 mln SEK per bid 1587: 2000 mln SEK per bid 147: 700 mln SEK per bid 576: 700 mln SEK per bid 520: 600 mln SEK per bid 2512: 200 mln SEK per bid 5536: 1000 mln SEK per bid Lowest permitted bid volume